ImmunoGen

Business

ImmunoGen bags priority review for full approval of ovarian cancer drug (NASDAQ:IMGN)

champpixs The U.S. Food and Drug Administration has granted ImmunoGen (NASDAQ:IMGN) a priority review for its supplemental biologics license application…

Read More »
Back to top button